MOESM6 of Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells
Fujun Li
Lixia Miao
Teng Xue
Hao Qin
Santanu Mondal
Paul Thompson
Scott Coonrod
Xiaoqiu Liu
Xuesen Zhang
10.6084/m9.figshare.9969257.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM6_of_Inhibiting_PAD2_enhances_the_anti-tumor_effect_of_docetaxel_in_tamoxifen-resistant_breast_cancer_cells/9969257
Additional file 6. Figure S6. Western blot analysis of the PAD2 knockdown (a) or miR-125b-5p overexpression (b) further decreased the levels of phosphorylated Akt and Rps6 phosphorylation in MCF7/TamR cells treated with 0.1 ÎźM docetaxel. GAPDH served as loading control. shCon: shRNA control MCF7/TamR cells; shPAD2: PAD2 knockdown cells; EV con: Empty vector pQXCIP overexpression MCF7/TamR cells; miR-125b-5p: miR-125b-5p overexpression; Doc: docetaxel; PBS was used as a control.
2019-10-11 05:37:27
Breast cancer
Tamoxifen-resistance
PAD2
Docetaxel